MetLife Investment Management LLC Makes New $209,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD)

MetLife Investment Management LLC purchased a new position in Kodiak Sciences Inc. (NASDAQ:KOD) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 21,040 shares of the company’s stock, valued at approximately $209,000.

Several other institutional investors and hedge funds have also made changes to their positions in KOD. Barclays PLC lifted its position in Kodiak Sciences by 65.5% in the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after purchasing an additional 31,527 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after buying an additional 30,735 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Kodiak Sciences in the fourth quarter valued at $1,660,000. Geode Capital Management LLC boosted its stake in Kodiak Sciences by 1.7% during the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after buying an additional 12,783 shares in the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in Kodiak Sciences during the fourth quarter worth about $236,000. 89.06% of the stock is currently owned by institutional investors.

Kodiak Sciences Stock Performance

NASDAQ KOD opened at $4.01 on Friday. Kodiak Sciences Inc. has a 1 year low of $1.92 and a 1 year high of $11.60. The business’s fifty day moving average is $3.28 and its two-hundred day moving average is $5.48. The stock has a market capitalization of $211.27 million, a P/E ratio of -1.10 and a beta of 2.42.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.06. On average, research analysts forecast that Kodiak Sciences Inc. will post -3.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.